Intern Xu Yingman Wei Jiali Lu Yuandong /p>
Time is precious to Ding Zhao. One week, one month, one year, these units don’t seem to be very different, and they always pass by in a flash. From a dialectical point of view, he will sigh that life is short, and he will also look forward to the early realization of the company’s vision. He firmly believes that by that day, Huiyu Pharmaceutical has become a respected international pharmaceutical company.
Ding Zhao Award (Photo by Lei Yuandong)
Ding Zhaosheng was born in 1985. At the age of 15, he went to study in the UK. He majored in biochemistry at Imperial College London for his undergraduate degree, and studied at the Department of Pharmacology at the University of Cambridge for his Ph.D. After obtaining a doctorate in pharmacology at the age of 25, he returned to his hometown of Neijiang, Sichuan to start a business and established Sichuan Huiyu Pharmaceutical Co., Ltd., mainly engaged in the research and development, production and sales of anti-tumor and injection drugs. In 2021, Huiyu Pharmaceutical will be listed on the Science and Technology Innovation Board.
On March 29, Ding Zhao was awarded “2021 Top Ten Economic Influential Persons in Sichuan”.
Roots
Biology class fell in love with genetics plotting to turn theory into application
Ding Zhao still remembers that biology class in junior high school. The first time he came into contact with DNA and genes, these new words made him novel, and he was full of interest in biomedicine.
“I want to transform the theory I was initially interested in into practical applications and create greater social value.” Driven by both curiosity and thirst for knowledge, Ding Zhao chose biochemistry as an undergraduate. majors, and then along this line, Ph.D. studies in pharmacology that can apply biochemical theory to disease. At the same time, he also took managerial economics as an elective to prepare for entrepreneurship after graduation.
Ding Zhao’s mother taught mathematics in junior high school and his father taught physics in high school. His parents’ words and deeds created a good family environment for him. Although his grades are already among the best, he still hasn’t relaxed his demands on himself.
When this habit of “being strong” became natural, he integrated it into the corporate culture: cancer is a difficult disease to overcome, and the complexity and mutation of cancer cells is hundreds of times stronger than that of the new coronavirus. After Ding Zhao established Huiyu Pharmaceutical, he not only focused on “overcoming” this world problem, but also with the mission of “providing global patients with medicines with exact curative effects, superb quality and reasonable price, and making cancer a manageable chronic disease”. .
Ding Zhao (photo courtesy of the interviewee)< /p>
Breakthrough
In order to survive the difficult period of starting a business, I lent my mother’s pension money
Ding Zhao has been studying abroad for many years, and his hometown complex always entangles Ding Zhao, with the feeling of a wanderer who contributes to his hometown. In 2010, he returned to his hometown in Neijiang, Sichuan, and founded Huiyu Pharmaceutical . The support and recognition of the company by the Neijiang Municipal Party Committee and Municipal Government has strengthened his confidence in his development.
In 2014, Huiyu Pharmaceutical passed the UK GMP certification for the first time, and in 2015, the drug was sold in the UK. He thought the future was bright, but reality hit him hard. In 2015 and 2016, due to the small sales volume and low profit, the company fell into development difficulties and was on the verge of bankruptcy at any time.
Compared with the supplier’s door-to-door debt collection, what worries Ding Zhao even more is that if the team’s talents are lost because the wages cannot be paid, the company will no longer have the possibility to come back to life. “I tried every means to ensure the payment of wages. Even the mother’s pension money was lent out in the most difficult time. With the support from the government, the company finally got through the difficulties.” Ding Zhao recalled those difficult years, still full of emotion. thousand.
The company ushered in a turning point in 2017. The first domestic drug Pemetrexed Disodium for Injection was approved, which was the first of its kind to pass the consistency evaluation. In 2018, “4+7” The pilot project of centralized procurement was launched, and the company became the only company that won the bid for pemetrexed disodium. The domestic market began to grow rapidly, and the foreign sales also grew steadily. In 2019, the company started the research and development of innovative drugs.
Growing
Re-development of unsatisfactory qualified products Excellent quality finally wins the market Recognition
Whether it is a corporate promotional video or an exclusive interview Ding Zhao has previously accepted, there is always a sentence, that is: “Everything can be stopped, just R&D cannot be stopped.” What does R&D mean to Huiyu Pharmaceutical? Ding Zhao answered this question with a set of data. The company currently has more than 1,500 people, including more than 500 R&D teams, accounting for one-third of the scale. For a comprehensive pharmaceutical company, the ratio of R&D personnel is the highest in the country and across the country. The world is higher.
“50% of my personal time is devoted to research and development.” Ding Zhao emphasized that the company is a research and development-driven enterprise, and only strong research and development can drive the company to continue to grow.
In 2015, when the company’s funds were quite tight, there was a drug that was actually qualified but did not achieve the expected effect. If it is re-developed, another 3-5 million will have to be invested. Knowing that reluctance to pass can save a lot of money, but Ding Zhao still decided to re-develop without hesitation, requiring products according to world-class standards.
Relying on the insistence on the quality of medicines, Huiyu currently has 11 first-line anti-tumor and related injections approved for marketing in the UK, and sold in more than 1,000 overseas medical institutions. Nine drugs have been approved for marketing in China, all of which are deemed to have passed the consistency evaluation of injections.
Ding Zhao (photo courtesy of the interviewee)
Blooming
Successful listing on the Sci-Tech Innovation Board and 2021 performance indicators continue to grow< /p>
On October 26, 2021, after 11 years of cultivation and irrigation, Huiyu Pharmaceutical ushered in a bloom and successfully listed on the Science and Technology Innovation Board.
For Ding Zhao, the listing has improved It has enhanced Huiyu’s popularity, enhanced the pride of the company’s employees, opened the door to the capital market for the company, and provided strong financial support for the research and development of innovative drugs, but this is only a phased achievement.
As a “new recruit” of the Science and Technology Innovation Board, the performance report shows that the company’s performance in 2021 is outstanding, and indicators such as total operating income, realized operating profit, and total realized profit have increased significantly compared with the same period of the previous year.
Ding Zhao is not proud of such performance, and objectively analyzed the reasons behind it. First, more and more products have been approved and entered the country for centralized procurement. Second, Huiyu’s sales system has become increasingly sound, and its brand awareness has gradually strengthened. The original variety has continued to grow.
Fruit breeding
Multiple projects are comprehensive Promoting down-to-earth struggle for dreams
About the field of tumor treatment, Huiyu Pharmaceutical Research Institute is divided into three major sections, one is responsible for generic drugs and complex injections, as well as improved new drugs. Research and development, three research institutes are responsible for the research and development of chemical innovative drugs, four are responsible for the research and development of biological innovative drugs, and there are support departments such as the Project Approval Department, the Intellectual Property Department, the Clinical Department, and the International and Domestic Registration Department. The company has more than 80 research projects, including 10. Class I innovative drug project.
The company also has 3 projects under construction, including the second phase project of Zeyu API production base and EU standard injection industrialization base located in Neijiang Economic and Technological Development Zone, and the second phase project of the industrialization base of EU standard injections in Chengdu. The innovative drug research institute base, after the completion of the project, will meet the expanding market demand and provide R&D and production capacity guarantee for the company’s subsequent approved varieties.
In view of the larger investment in R&D of innovative drugs than generic drugs, the approval cycle is long , In order to allow high-quality drugs to be accepted by patients at a reasonable price, while ensuring the company’s short- and medium-term profit growth and supporting the company’s increasing R&D investment, the current development rhythm of Huiyu Pharmaceutical is to continue to develop generic drug R&D, while focusing on accelerating The pace of research and development of innovative drugs.
Ding Zhao set an appointment for the company for the next ten years, hoping that after ten years, the company will complete the transition from “imitation and innovation” to “combination of imitation and innovation”, and Towards “innovation-oriented”. In the research and development of innovative drugs, follow the principle of “no one has my own, and everyone has my own essence” Therefore, through continuous exploration and innovation, it will reflect better clinical value among similar drugs, and truly enable cancer patients to receive better treatment and be full of hope for life.
Although he ridiculed himself as “living on a treadmill every day”, Ding Zhao’s mentality is not impetuous due to the fast-paced life, but down-to-earth to make the dream closer.
【If you have news clues, welcome to report to us. Once adopted, you will be paid a fee. Newsletter WeChat Follow: ihxdsb, Newsletter QQ: 3386405712]